Oruka Therapeutics ($ORKA) Stock Hub: Can Oruka turn lasting skin clearance into a differentiated psoriasis franchise?

01 Full Bull, Base and Bear Scenarios

The scenarios below describe evidence patterns, not probabilities or price forecasts.

Constructive scenario

EVERLAST-B reproduces high PASI 100 rates in the 600 mg and 300 mg arms with a low placebo rate and a sensible dose response. In December, the 52-week EVERLAST-A data show that a large share of Week 28 responders randomized to no further dosing remain clear for a long interval, with limited retreatment. ORCA-SURGE then shows competitive clearance for ORKA-002 in the first quarter of 2027, and the ORKA-001 Phase 3 program starts in the first half of 2027 as guided. In that sequence, Oruka would hold two differentiated psoriasis assets, financed through a BLA filing on the company’s own guidance.

Intermediate scenario

The trials succeed, but the detail narrows the story: the lower dose underperforms, the maintenance data point to dosing every six months rather than yearly, or ORKA-002 lands close to existing IL-17 therapy without a clear edge. The programs advance while the valuation remains contested, and the ATM and outstanding awards add share supply during a long, expensive Phase 3 period.

Adverse scenario

EVERLAST-B shows weaker replication than EVERLAST-A, durability wanes once retreatment and missing data are counted, a safety signal emerges with longer exposure, or timelines slip. Any of these would lower the probability of a differentiated product and could compress the valuation sharply, even with more than $1 billion in cash, because cash covers only a fraction of the equity value.

What Would Falsify This Reading

The reading presented here is that ORKA-001 has shown deep, early and so far durable skin clearance in a small Phase 2a study, that Oruka is funded through an ORKA-001 BLA filing on its own guidance, and that the open questions are replication, maintenance interval, long-term safety and a valuation that already prices much of that success. The following developments, each observable in a company release, an SEC filing or a registry update, would contradict that reading.

• EVERLAST-B fails to replicate. A 600 mg arm well below the 63.5% Week 16 PASI 100 seen in EVERLAST-A, or a high placebo rate, would suggest the first study overstated the effect.
• Durability fades in December. If most Week 28 PASI 100 patients randomized to no further dosing lose response before Week 52, the yearly-dosing argument weakens and the product converges on incumbent schedules.
• A safety signal with long exposure. A treatment-related serious adverse event pattern, or an anti-drug-antibody effect not seen through Week 28, would matter more for a long-acting antibody than for a shorter-acting one.
• Guidance slips. A move of EVERLAST-B beyond the fourth quarter of 2026, of ORCA-SURGE beyond the first quarter of 2027, or of the Phase 3 start beyond the first half of 2027 would challenge the execution record.
• Funding language changes. Any retreat from the statement that cash funds the company through an ORKA-001 BLA filing, or heavy ATM use at lower prices, would weaken the balance-sheet pillar of this reading.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

02 Company history: a new immunology business inside an older listing

The operating Oruka business was formed in February 2024 around rights to antibodies developed by Paragon. Its merger with ARCA closed on August 29, 2024; post-merger, split-adjusted trading began on September 3. Headquarters are in Menlo Park. 2025 Form 10-K

The present business model is straightforward: fund and develop proprietary biologics, validate a differentiated clinical profile and ultimately seek commercialization or a suitable partnership. There is no current product-sales base to anchor a conventional earnings multiple. The most relevant operating output is credible clinical evidence, followed by the ability to convert that evidence into an approvable and commercially competitive regimen.

The financing history since the merger explains the size of the June 30, 2026 balance sheet better than the predecessor’s chart does. The Q2 2026 Form 10-Q states that operations have been funded mainly through convertible preferred stock, common stock, a convertible note and pre-funded warrants, with an accumulated deficit of $262.2 million at June 30, 2026. The largest single step came after the April 2026 Week 16 data: Oruka priced an upsized underwritten offering of 9,660,000 shares at $72.50, for gross proceeds of about $700.4 million, with net proceeds of $658.3 million reported in the cash-flow statement. Offering pricing release · Q2 2026 Form 10-Q

03 Leadership, governance and alignment

CEO Lawrence Klein previously worked at Versant and held Chief Business Officer and Chief Operating Officer roles at CRISPR Therapeutics. CMO Joana Goncalves brings experience from Cara and the OTEZLA program at Celgene. CEO biography · CMO biography

Todd Edwards, appointed Chief Commercial Officer in August, previously led commercial work at Arcutis and held immunology roles at Incyte and UCB. The August 24, 2026 Form 8-K adds detail: Edwards, 63, was Executive Vice President and Chief Commercial Officer of Arcutis Biotherapeutics from December 2024 to August 2026, after serving as its Senior Vice President and Chief Commercial Officer from September 2023, and before that led Incyte’s dermatology business unit as Group Vice President from December 2020. That background is relevant to eventual access and launch planning; it is not evidence that a launch date has been established. Commercial leadership biography · Appointment announcement · Form 8-K

Other officers who appear in recent SEC filings are Chief Operating Officer Laura Sandler, General Counsel Paul Quinlan and Senior Vice President of Finance Arjun Agarwal. Their Form 4 reports show compensation concentrated in low-priced warrants and options, which aligns management with the equity and makes plan-based selling a routine feature of the register.

The April proxy identifies Samarth Kulkarni as board chair and a staggered, three-class board. Other directors include Kristine Ball, Carl Dambkowski, Peter Harwin and Chris Martin. 2026 proxy statement

Governance deserves attention because Fairmount, Paragon and Oruka have overlapping economic relationships. Fairmount has board representation and interests in the licensor. Related-party arrangements can bring specialist expertise and access to assets, but investors should examine licensing terms and capital allocation independently. The appropriate management scorecard is practical: truthful schedule updates, transparent denominators, sensible Phase 3 design and disciplined spending.

04 What Oruka is trying to improve

Oruka’s engineering strategy combines target binding, longer antibody circulation and formulation work. The goal is to maintain useful exposure for longer while preserving efficacy, tolerability and manufacturability. ORKA-001 targets IL-23p19; ORKA-002 targets IL-17A/F. These are established inflammatory pathways, but each investigational molecule must establish its own benefit-risk profile. Company pipeline and engineering overview

A long pharmacokinetic half-life describes how slowly drug levels fall. It does not automatically establish how long a patient remains clear, how quickly symptoms return, or which minimum exposure is required. Clinical durability must be measured in the intended population. The distinction is especially important when extrapolating from healthy-volunteer blood concentrations to chronic inflammatory disease.

PASI 100 means complete improvement in the Psoriasis Area and Severity Index relative to baseline; PASI 90 means at least 90% improvement. These are useful efficacy endpoints, but investors should also consider physician assessments, patient-reported burden, rescue treatment, discontinuations and missing-data handling. A compelling curve can become less compelling if maintenance requires extensive rescue dosing or if favorable results depend on selecting only the best initial responders.

The mechanism behind the dosing ambition is specific. The Q2 2026 Form 10-Q describes ORKA-001 as carrying YTE half-life extension, a three-amino-acid change in the Fc domain that alters pH-dependent binding to the neonatal Fc receptor, FcRn, so that the antibody is recycled rather than degraded. In the completed Phase 1 study in healthy volunteers, the company reports a human half-life of approximately 100 days, and states that a single 600 mg dose kept ORKA-001 concentrations well above effective trough levels through Week 52, the last time point evaluated, with sustained inhibition of IL-23 pathway signaling. Q2 2026 Form 10-Q · Phase 1 registry record

For ORKA-002 the same logic applies to a different target. The company says the antibody was designed to bind IL-17A and IL-17F at epitopes and affinity ranges similar to bimekizumab, the dual inhibitor marketed as BIMZELX, while adding half-life extension. The interim Phase 1 half-life of roughly 75 to 80 days is the basis for the company’s proposed twice-yearly maintenance in psoriasis and quarterly maintenance in hidradenitis suppurativa. Both are design targets until patient trials confirm them; the 10-Q also flags that a longer half-life may be perceived as prolonging side effects. Q2 2026 Form 10-Q

05 Pipeline map: separate current programs from optionality

September pipeline deck · Annual filing

The pipeline is not five independent, equally mature assets. Two programs currently carry most of the near-term evidence burden. The earlier programs are options on future development, with additional formulation, safety, trial-design and funding requirements. Combining antibodies also increases complexity: success of each individual component does not establish that a combination improves outcomes enough to justify its cost or exposure.

ClinicalTrials.gov records, as of October 2, 2026, give a useful status snapshot. EVERLAST-A (NCT07090330) and EVERLAST-B (NCT07290569) are listed as active and no longer recruiting. ORCA-SURGE (NCT07474792) and ORCA-SPLASH (NCT07783542) are listed as recruiting, as is the open-label extension (NCT07449702). The ORKA-002 Phase 1 study in healthy volunteers remains active, while the ORKA-001 Phase 1 study is listed as completed. Registry enrollment figures are sponsor estimates and can lag company disclosures: EVERLAST-B, for example, is still shown at 160 participants while the company reports 187 enrolled.

06 EVERLAST-A: what the completed results establish

EVERLAST-A enrolled 84 patients, randomized 3:1. The active arm received 600 mg at Weeks 0 and 4. At Week 16, PASI 100 was achieved by 40/63 patients (63.5%), against 1 of 21 on placebo (4.8%); the same single placebo patient also reached PASI 90, IGA 0 and IGA 0/1. PASI 90 was reached by 83% and IGA 0/1 by 84% of treated patients. Adverse-event rates were 51% with active treatment and 57% with placebo; upper respiratory tract infection was the most common event (19% versus 14%), there were no serious treatment-emergent events in the ORKA-001 group and no injection-site reactions. April 27 data release

On September 23, Oruka reported Week 28 PASI 100 of 45/63 (71.4%), PASI 90 of 55/63 (87.3%), and IGA 0/1 of 53/63 (84.1%). No further initial-arm dosing occurred after Week 4. Patients who started on placebo received 600 mg at Weeks 16 and 20, and 40.0% of them reached PASI 100 at Week 28, only eight to twelve weeks after their doses. Between Weeks 16 and 28, upper respiratory tract infection was the only adverse event in at least 5% of patients (8%, 7 of 83); two serious events were reported as not drug-related; there were no injection-site reactions and the company reported no impact of anti-drug antibodies on safety, efficacy or pharmacokinetics. These are company-reported results, not a guarantee of later safety. Week 28 update

The release quotes Bruce Strober, Clinical Professor of Dermatology at Yale University School of Medicine: “The depth of clearance seen at Week 28, achieved without any dosing beyond Week 4, is remarkable.” The study ran across 26 sites in the United States and Canada. The Week 28 milestone also triggers the maintenance part of the design: according to the Q2 10-Q, patients with PASI 100 at Week 28 are randomized 2:1 either to receive no further dose until disease recurrence, which tests yearly dosing and off-treatment remission, or to receive 300 mg every six months. That is the comparison the December release should make visible. Q2 2026 Form 10-Q

07 EVERLAST-B: reproducibility and dose selection

The September deck identifies EVERLAST-B as NCT07290569, with 187 participants, four randomized groups and PASI 100 at Week 16 as the primary endpoint. Active induction regimens include 600 mg and 300 mg at Weeks 0 and 4, plus a deliberately low single 37.5 mg dose at Week 0; the fourth group is placebo. The Q2 10-Q describes the second stage: at Week 28, patients with PASI 100 are re-randomized 1:1 to 600 mg once yearly or placebo, while patients without PASI 100 receive 300 mg every six months. Placebo patients can roll into the open-label extension at Week 28. Trial design, slide 18 · Trial registry

Management expects the results in Q4 2026 and intends them to support a Phase 3 start in the first half of 2027. A successful Phase 2b study would improve the development case; it would not complete the evidence required for approval.

A practical benchmark exists inside Oruka’s own data. In EVERLAST-A, 600 mg at Weeks 0 and 4 produced 63.5% PASI 100 at Week 16 with a 4.8% placebo rate in a small population. EVERLAST-B repeats that regimen in a larger, multi-arm setting, so the 600 mg arm offers the cleanest replication test. A materially lower result in that arm would not end the program, but it would suggest that the first study flattered the effect. The 300 mg arm addresses cost and manufacturing: if it performs close to 600 mg, the commercial product could need less antibody per patient. The registry lists 36 locations and a primary completion date in June 2027, which reflects the longer maintenance stage rather than the Week 16 readout guided for the fourth quarter of 2026. Trial registry

08 ORKA-002: another mechanism, another proof requirement

The initial ORKA-002 study involved 24 healthy adults across three ascending-dose cohorts. January data indicated a 75–80 day half-life and no serious or severe treatment-emergent events in the interim report. The twice-yearly psoriasis maintenance concept was supported by modeling, not demonstrated patient efficacy at that point. January Phase 1 release

ORCA-SURGE is designed around roughly 160 patients, three active dose groups and placebo, with Week 16 PASI 100 as its primary endpoint. The active induction doses are 40, 160 and 320 mg at Weeks 0 and 4. The current readout window is Q1 2027. Study design · Updated timing · NCT07474792

This is the most useful diversification in the near-term calendar: an efficacy test of another molecule against a different inflammatory target. Nevertheless, it shares commercial exposure to psoriasis and some organizational risks with ORKA-001. It is not an independent hedge against a sector selloff, manufacturing problems or a reassessment of convenience-based differentiation.

The registry record adds detail on who is being studied. ORCA-SURGE enrolls adults aged 18 to 79 with plaque psoriasis for more than six months, body-surface involvement of at least 10%, PASI of at least 12 and an IGA score of at least 3, the conventional entry criteria for moderate-to-severe disease. Safety, including adverse events of special interest, is followed through Week 48. As of October 2, 2026, the study was listed as recruiting at 39 locations in the United States and Canada, with a registry primary completion date of October 2027 and study completion in April 2029. For a Week 16 readout in the first quarter of 2027, enrollment needs to close around the end of 2026; that is an inference from the trial design, not a company statement, and any change to the guided window would be the first observable signal. NCT07474792

09 HS, TL1A and the next layer of optionality

ORCA-SPLASH studies ORKA-002 in hidradenitis suppurativa. The planned approximately 160-patient trial compares 320 mg against placebo at Weeks 0/4/8/12, with HiSCR75 at Week 16 as the primary endpoint and an open-label maintenance period. The registry record (NCT07783542) shows a start date of August 21, 2026, 15 locations at the time of checking on October 2, 2026, an estimated enrollment of 200 participants against the company’s description of about 160, and a primary completion date of October 2028. No readout window has been guided by the company, so none is included in the catalyst calendar. August development update

HS is not simply psoriasis with another label. Disease burden, lesion assessment, patient variability and the clinical bar differ. A positive psoriasis result would validate aspects of the molecule but would not settle HS efficacy. Investors should resist adding the full addressable markets of both indications before each has clinical support.

ORKA-004’s planned clinical entry is a development milestone, below an efficacy readout in immediate evidentiary weight. The TL1A combination strategy offers a route to deeper control or broader indications, but currently adds uncertainty about patient selection, contribution of each component and regulatory expectations. Merlintrader does not assign a probability-adjusted dollar value.

10 Catalyst calendar: remaining events and their quality

Latest ORKA-001 timing · Program schedule · September confirmation

The company has not committed to exact announcement days for the three main readouts. EVERLAST-B and the December durability update could arrive close together; ORCA-SURGE follows in the next quarter. September 23 Week 28 results are completed and excluded from the upcoming list. The company attended the Morgan Stanley Global Healthcare Conference in New York on September 14–16, 2026, and no change to these windows was announced through October 2, 2026. Conference notice

11 Cash, spending and the development budget

Q2 financial release · Q1 release · Cash-flow statement and subsequent events

Year-over-year, the quarter shows a company scaling up its trials. Q2 2026 R&D expense of $43.3 million compares with $24.1 million in Q2 2025, and G&A of $6.9 million with $4.3 million. Other income, net, mostly interest on the larger cash pile, rose to $8.9 million from $3.9 million, which is why the net loss of $41.2 million is smaller than total operating expense. Net loss per common share was $0.55 on 62,872,318 weighted-average shares, against $0.46 a year earlier. The six-month net loss was $73.0 million. Q2 financial release

The cash-flow statement shows where the money came from in the first half: $703.6 million of net financing inflows, including $658.3 million from the April offering, $38.9 million from the ATM program and $6.1 million from option and employee-warrant exercises. Investing outflows of $425.4 million mostly reflect $581.4 million of marketable-securities purchases, partly offset by $156.1 million of maturities. Q2 2026 Form 10-Q

Management says cash, cash equivalents and marketable securities of $1.1 billion are expected to fund the company through a BLA filing for ORKA-001; the formal going-concern language in the 10-Q is narrower, at least twelve months from the filing date. That is a plan-dependent runway statement, not a fixed calendar guarantee. Phase 3 expansion, combination studies, manufacturing commitments and commercial preparation can materially increase spending. Extrapolating the first-half burn into a decade of runway would be misleading.

12 Capital structure and dilution: ordinary shares are only the start

The SEC cover reports 66,209,699 common shares at July 31. Add 7,874,739 common equivalents from remaining preferred stock after July’s conversion and 5,706,188 June pre-funded warrants: approximately 79.79 million. This mixes disclosed dates and assumes no subsequent warrant changes; it is not a current fully diluted denominator. Q2 filing, cover and Notes 7/13

Other outstanding instruments are listed in the August 27, 2026 prospectus, all at June 30, 2026: 5,227,356 stock options with a weighted-average exercise price of $20.64; 2,619,353 employee warrants at a weighted average of $7.80; 971,930 warrants tied to the Paruka warrant obligation at a weighted average of $23.55; and 409,922 restricted stock units. A further 5,910,376 shares were reserved under the 2024 Stock Incentive Plan and 963,033 under the Employee Stock Purchase Plan. Each weighted-average exercise price is well below the October 1, 2026 close, so these roughly 9.2 million award shares represent likely future supply, partly offset by cash paid on exercise. Awards require attention to exercise prices, vesting and potential proceeds; simply adding authorized but unissued shares is not a sensible diluted-value calculation. Prospectus capital exclusions

The latest prospectus covers up to $500 million of ATM sales. The older $35.3 million remaining-capacity figure after July is therefore not the current facility description. Actual subsequent sales have not been established here. Capacity authorizes potential issuance; it is not cash already received.

The ATM is a TD Cowen sales agreement first signed on October 3, 2025 and amended on August 21, 2026, with commissions of up to 3.0% of gross proceeds; the $500 million sits within a $1.0 billion shelf registration filed on August 21 and declared effective on August 27, 2026. Under the previous capacity, Oruka sold 1,499,500 shares in July 2026 at an average of $83.35, for net proceeds of $122.5 million. At a hypothetical $83.42 sale price, the October 1, 2026 close, $500 million would correspond to approximately 5.99 million new shares before fees. This is arithmetic illustrating possible share supply, not a forecast of sales.

The prospectus also quantifies book dilution. Net tangible book value at June 30, 2026 was $1,114.5 million, or $18.25 per share on 61,069,887 shares. Its illustrative example, selling 4,768,262 shares at $104.86, the August 20, 2026 close, would lift net tangible book value per share to $24.29. The gap between book value and market price is the premium investors pay for the pipeline, not a measure of value lost. August 27, 2026 prospectus · Form S-3

13 Institutions and insiders: useful evidence with dated boundaries

The most reliable ownership evidence comes from Schedule 13D and 13G filings, in which holders above 5% report their own positions under SEC rules. The table below is based on those primary filings rather than third-party data aggregations. Each line carries its own reference date and share base, so the percentages are not additive and do not describe the register at the October 1, 2026 close.

Fairmount’s figure is the most important to read correctly. It includes 7,874,739 shares issuable on conversion of the remaining 94,497 Series B preferred shares and 2,973,894 shares under pre-funded warrants, and excludes a further 2,323,770 pre-funded-warrant shares that sit above a 9.99% exercise limitation. The 13D computes the percentage on 74,733,166 shares, a base that combines the April 30 share count with the July 1 conversion and exercisable awards. On July 1, 2026 Fairmount converted preferred stock into 3,553,410 common shares and sold them at $84.43; the conversion itself did not create new cash for Oruka. Fairmount Form 4

Insider selling in September 2026 was frequent but structured. On September 1, CEO Lawrence Klein exercised 75,000 employee warrants at $7.80 and sold 75,000 shares at weighted averages between $90.79 and $92.44 under a Rule 10b5-1 plan adopted on May 14, 2026, leaving 925,580 directly held shares; on September 15 an automatic sell-to-cover sold 2,452 shares at $95.71 for tax withholding, leaving 923,128. On October 1 he filed a Form 144 for a proposed sale of 25,000 shares acquired through an option exercise under the same plan. Form 4, September 1 · Form 4, September 15 · Form 144, October 1

Other officers followed the same pattern. COO Laura Sandler exercised and sold 5,000 warrant shares on September 1 under a plan adopted on September 19, 2025, keeping 235,478 shares after a later sell-to-cover. CMO Joana Goncalves exercised 7,000 options and warrants on September 15 and sold them under a plan also adopted on September 19, 2025, plus an automatic sell-to-cover sale of 947 shares at $95.71 for tax withholding, keeping 31,771. General Counsel Paul Quinlan exercised and sold 10,000 warrant shares on September 21 under a plan adopted on May 15, 2026, keeping 29,995. Senior Vice President of Finance Arjun Agarwal sold 9,459 option shares on September 11 and 533 shares on September 21 under a February 11, 2026 plan. Sandler · Goncalves · Quinlan · Agarwal

Plan-based sales fixed months in advance and tax-withholding sales are not discretionary bearish calls; equally, no open-market insider purchase appears in the Forms 4 filed in August and September 2026. A 13G reports a past date, and specialist ownership does not offset adverse clinical evidence.

14 Competition: the bar is already high

SKYRIZI dosing · TREMFYA dosing · BIMZELX dosing and safety · ICOTYDE approval

These regimens are context, not treatment recommendations or a claim of comparative efficacy. Different study populations, follow-up periods, endpoints and missing-data rules make cross-trial rankings uncertain. ORKA-001 has not established head-to-head superiority over these products.

Commercial differentiation can come from several sources: clearance, speed, durability, ease of administration, safety, adherence and cost. An attractive dosing interval may lose impact if induction is burdensome, payers prefer discounted alternatives or patients are reluctant to switch a working therapy. Oruka must eventually compete against the complete incumbent offering, including evidence, access programs and physician confidence, rather than against a single dosing-frequency statistic.

The competitive map also matters for ORKA-002 in a specific way. The 10-Q notes that dual IL-17A and IL-17F blockade with bimekizumab has produced higher response rates than blocking IL-17A alone, which is the scientific rationale for ORKA-002, and that the antibody was designed to bind similar epitopes. That makes BIMZELX both the proof of concept and the commercial incumbent: ORKA-002 needs to match its efficacy in patients and show that longer dosing intervals do not come with a different safety profile. ICOTYDE, approved by the FDA on March 18, 2026 as a once-daily oral peptide (J&J release), competes from the other direction by removing injections altogether. Q2 2026 Form 10-Q

15 Rights, patents and manufacturing economics

In May 2026, Oruka amended its IL-23 license with Paragon to cover all therapeutic areas, including inflammatory bowel disease, which had previously been excluded. The August 10 results release says the change permits development of ORKA-001 or combinations in IBD, subject to timing restrictions on starting clinical trials. Expanded rights are not a completed IBD trial or proof of efficacy in that indication. Oruka Q2 2026 financial results release.

The annual filing describes exclusive Paragon licenses for ORKA-001 and ORKA-002. It indicates 2045 expiry for certain ORKA-001 patent rights and, if issued, relevant ORKA-002 rights, before applicable adjustments or extensions. These statements do not establish a universal 2045 exclusivity guarantee. Intellectual-property disclosures

The Paragon agreements carry development/regulatory milestones and low-single-digit royalties. The company also licensed Halozyme Hypercon technology for formulation work; the Q1 update describes its potential to improve the eventual product profile. License terms · Formulation collaboration

16 Valuation framework: strong science is not the same as a cheap stock

At the October 1, 2026 close of $83.42, ordinary equity value is about $5.52 billion on the 66,209,699 shares reported at July 31, 2026. Subtracting June 30 cash and securities of $1,125.6 million gives approximately $4.40 billion; adding the July ATM net proceeds of $122.5 million to cash, since the corresponding shares are already in the July count, brings the figure to about $4.28 billion before subsequent operating cash use. Q2 2026 Form 10-Q

Using the broader base of 79,790,626 common equivalents, which adds the 7,874,739 preferred-conversion shares and the 5,706,188 pre-funded warrants, the same price gives approximately $6.66 billion of equity value and roughly $5.41 billion after cash including July proceeds. These are deliberately labeled reference calculations combining figures with different dates, not a completed enterprise-value bridge. They show why the capital denominator materially changes the apparent cost of the pipeline.

A defensible valuation would model each indication separately: probability of technical and regulatory success, launch timing, eligible patients, uptake, net realized price, royalty burden, development cost and future financing. It would then discount future cash flows and divide by a consistent diluted share base. An unsupported peak-sales multiple or a broker target cannot substitute for those assumptions.

No Merlintrader target price or implied return is assigned. Good data must raise the probability of a valuable franchise, or reduce development risk, enough to justify a hurdle that is already substantial.

Analyst coverage: the Finviz aggregate of third-party estimates, as of October 2, 2026, showed a mean price target of $153.15. It is an average of opinions from individual firms, it is not company guidance, and it is not a measure of fair value. The April 2026 offering was led by Leerink Partners, TD Cowen, Goldman Sachs, Stifel and Guggenheim Securities, and TD Cowen is also the ATM agent, a relationship worth keeping in mind when reading research from underwriting banks. Offering pricing release

17 Short interest, liquidity and the difference between a debate and a squeeze

Short interest at the September 15, 2026 settlement was 7.62 million shares. Nasdaq puts that at about 11.6 days to cover, based on average daily volume of 656,686 shares for the period (Nasdaq short interest). The Finviz aggregate as of October 2, 2026 put short interest at 12.97% of float, institutional ownership at 103.56% and insider ownership at 11.21%; an institutional figure above 100% reflects overlapping 13F reports, not literal ownership.

This is meaningful positioning, not a tiny-float setup. Shorts may cover after a strong result, add after a disappointment or stay hedged; Merlintrader has no verified data on borrow fees, utilization or option positioning and does not estimate them.

The Week 28 release is a useful case study in expectations. The shares closed at $94.55 on September 22, 2026 and at $89.93 on September 23, the day positive data were published, and at $83.42 on October 1. A positive study can coincide with a weaker share price when expectations were higher or when investors focus on what the data do not yet show, here the maintenance results and the larger EVERLAST-B dataset. The primary documents establish the clinical results; they do not identify the motives of each seller.

18 The evidence checklist for each upcoming readout

Each catalyst answers a different question, so each needs its own reading list. The checklist below sets out, before the data arrive, what a complete disclosure should contain and which number matters most. It uses Oruka’s own earlier results as the reference point, because cross-trial comparisons with other companies’ studies are unreliable.

Evidence that would improve confidence: complete randomized tables, denominators and confidence intervals; outcomes by maintenance assignment; retreatment rates; a transparent Phase 3 plan; safety across longer exposure; and a clear quarter-end capital structure in the Q3 2026 Form 10-Q. These are observable checks, not demands for perfect results.